Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update

Rhea-AI Summary

Rigel (Nasdaq: RIGL) will report fourth quarter and full year 2025 financial results after market close on Tuesday, March 3, 2026. A live conference call and webcast will follow at 4:30 p.m. ET to review results and provide a business update.

Investors can join by phone or via the Investor Relations webcast at www.rigel.com; the webcast will be archived for 90 days.

Key Figures

Earnings release date: March 3, 2026 Conference call time ET: 4:30 p.m. Eastern Time Conference call time PT: 1:30 p.m. Pacific Time +4 more

7 metrics

Earnings release date March 3, 2026 Scheduled Q4 and full-year 2025 financial results

Conference call time ET 4:30 p.m. Eastern Time Time of earnings call following results release

Conference call time PT 1:30 p.m. Pacific Time Local time for company headquarters region

Domestic dial-in 877-407-3088 US phone access for live conference call

International dial-in 201-389-0927 International phone access for live conference call

Webcast replay period 90 days Archived webcast availability on Rigel website

Company founding year 1996 Rigel founding date mentioned in company description

Market Reality Check

Price: $34.26 Vol: Volume 263,828 is slightl...

normal vol

$34.26 Last Close

Volume Volume 263,828 is slightly below the 20-day average of 286,168 (relative volume 0.92) ahead of the earnings call. normal

Technical Shares at $34.26 are trading above the 200-day moving average of $31.8 and about one-third below the 52-week high of $52.24.

Peers on Argus

RIGL was down 3.38% ahead of this neutral scheduling news, while momentum-screen...

2 Up

RIGL was down 3.38% ahead of this neutral scheduling news, while momentum-screened biotech peers like VIR and PVLA showed strong upside moves. Broader peer price action appears mixed, suggesting a stock-specific setup rather than a clear sector-wide move.

Common Catalyst Some peers, such as PVLA, had clinical trial updates, whereas RIGL’s item is purely an earnings call announcement.

Historical Context

5 past events · Latest: Feb 03 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 03	Board appointment	Positive	+0.5%	New director with extensive biotech and pharma commercial experience joined board.
Jan 15	Clinical trial start	Positive	-0.8%	First patient enrolled in Phase 1b/2 AML trial combining REZLIDHIA with other agents.
Jan 12	Business update	Positive	-2.1%	Preliminary Q4 and 2025 revenues plus 2026 revenue and income outlook provided.
Jan 09	Equity inducements	Neutral	-8.2%	Stock options and RSUs granted to new non-executive employees under inducement plan.
Jan 07	Conference appearance	Positive	+8.7%	CEO presented company overview at J.P. Morgan Healthcare Conference webcast.

Pattern Detected

Recent positive clinical and business updates have sometimes seen muted or negative next-day moves, while conference visibility has coincided with stronger gains.

Recent Company History

Over the last few months, Rigel issued several operational and strategic updates. A Jan 2026 business update outlined preliminary Q4 and full-year 2025 revenues and a 2026 outlook. Earlier, the company reported Phase 1b/2 trial initiation for REZLIDHIA combinations in AML and announced inducement equity grants. Corporate visibility increased with a presentation at the 44th J.P. Morgan Healthcare Conference and a new board appointment. Today’s release simply sets the timetable for formal Q4 and full-year 2025 financial reporting.

Market Pulse Summary

This announcement simply sets the timing for Rigel’s Q4 and full-year 2025 results on March 3, 2026 ...

Analysis

This announcement simply sets the timing for Rigel’s Q4 and full-year 2025 results on March 3, 2026 and outlines access details for the call and webcast. It follows recent business updates, clinical developments, and conference appearances that shaped expectations for revenue and strategy. Investors may focus on how the reported figures compare with the previously shared 2025 revenue levels and 2026 outlook, as well as any pipeline or commercial updates shared on the call.

Key Terms

hematologic disorders

1 terms

hematologic disorders medical

"novel therapies that significantly improve the lives of patients with hematologic disorders and cancer."

Hematologic disorders are diseases that affect the blood and the organs that make blood, such as conditions causing low blood counts, abnormal clotting, or cancers of blood-forming cells. For investors, these disorders matter because they define markets for diagnostics, treatments and long-term care—think of them as problems in a city’s delivery and maintenance system: fixing them can create commercial opportunities, while persistent unmet needs can drive regulatory attention and spending.

AI-generated analysis. Not financial advice.

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its fourth quarter and full year 2025 financial results after market close on Tuesday, March 3, 2026. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and give an update on the business.

Participants can access the live conference call by dialing 877-407-3088 (domestic) or 201-389-0927 (international). The conference call and accompanying slides will also be webcast live and can be accessed from the Investor Relations section of the company's website at www.rigel.com. The webcast will be archived and available for replay for 90 days after the call via the Rigel website.

About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit www.rigel.com.

Contact for Investors & Media:
Investors:
Rigel Pharmaceuticals, Inc.
650.624.1232
ir@rigel.com 

Media:
David Rosen
Argot Partners
Phone: 646.461.6387
Email: david.rosen@argotpartners.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-announces-conference-call-and-webcast-to-report-fourth-quarter-and-full-year-2025-financial-results-and-business-update-302695322.html

SOURCE Rigel Pharmaceuticals, Inc.

FAQ

When will Rigel (RIGL) report Q4 and full year 2025 results?

Rigel will report results after market close on March 3, 2026. According to the company, senior management will host a live conference call and webcast at 4:30 p.m. ET the same day to discuss financial results and a business update.

How can investors access the Rigel (RIGL) March 3, 2026 earnings call?

Investors can join by phone or webcast via the company website. According to the company, domestic callers may dial 877-407-3088 and international callers 201-389-0927, or use the Investor Relations webcast at www.rigel.com.

What time is the Rigel (RIGL) conference call for Q4 and FY2025 results?

The conference call is scheduled for 4:30 p.m. Eastern Time on March 3, 2026. According to the company, this follows the after-market release of fourth quarter and full year 2025 financial results.

Will the Rigel (RIGL) earnings webcast be available after the live call?

Yes, the webcast will be archived for replay for 90 days after the call. According to the company, the archived webcast can be accessed via the Investor Relations section at www.rigel.com for on-demand review.

Where can I find Rigel (RIGL) investor materials and the call slides?

Call slides and materials will be available on Rigel's Investor Relations website. According to the company, the conference call and accompanying slides will be webcast live and posted at www.rigel.com.

Who will present on Rigel's (RIGL) March 3, 2026 earnings call?

Rigel senior management will present on the live call and webcast. According to the company, management will discuss the fourth quarter and full year 2025 financial results and provide an update on the business.